Literature DB >> 22265733

The effect of hormonal treatment on conspicuity of prostate cancer: implications for focal boosting radiotherapy.

Greetje Groenendaal1, Marco van Vulpen, Susanne R Pereboom, Davey Poelma-Tap, Johannes G Korporaal, Evelyn Monninkhof, Uulke A van der Heide.   

Abstract

BACKGROUND AND
PURPOSE: For focal boosting of prostate tumors, three questions are important regarding the use of hormonal therapy. Does prolonged hormonal treatment affect the conspicuity of tumor tissue on diffusion weighted imaging (DWI) and dynamic contrast-enhanced (DCE-MRI) images? Is tumor delineation possible in patients using hormonal treatment? Can we identify specific imaging thresholds for tumor delineation in patients after prolonged androgen deprivation?
MATERIALS AND METHODS: Ninety-six patients were included. Using multivariate linear regression analyses, we investigated if DWI and DCE-MRI parameter maps are different in patients receiving hormonal treatment for 0-3 or >3 months. Furthermore, logistic regression was performed to obtain specific imaging thresholds for tumor tissue for the two patient groups.
RESULTS: We found a significantly higher diffusion and lower perfusion of tumor tissue in the >3 months hormonal treatment group compared to the 0-3 group. This resulted in lower tumor conspicuity. Nevertheless, in 18/21 of the patients in the >3 months treatment group, a suspicious lesion could be defined based on the MR images. Based on logistic regression, different imaging thresholds should be set for tumor detection in the two treatment groups.
CONCLUSIONS: Prolonged androgen deprivation decreases tumor conspicuity. Different imaging thresholds need to be set to delineate tumor in patients who have had prolonged hormonal treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265733     DOI: 10.1016/j.radonc.2011.12.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort.

Authors:  Olga Starobinets; John Kurhanewicz; Susan M Noworolski
Journal:  NMR Biomed       Date:  2017-02-06       Impact factor: 4.044

2.  Changes in prostate apparent diffusion coefficient values during radiotherapy after neoadjuvant hormones.

Authors:  Andrew McPartlin; Lucy Kershaw; Alan McWilliam; Marcus Ben Taylor; Clare Hodgson; Marcel van Herk; Ananya Choudhury
Journal:  Ther Adv Urol       Date:  2018-10-11

3.  Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.

Authors:  Louise J Murray; John Lilley; Christopher M Thompson; Vivian Cosgrove; Josh Mason; Jonathan Sykes; Kevin Franks; David Sebag-Montefiore; Ann M Henry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

4.  Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy.

Authors:  Ulrika Björeland; Tufve Nyholm; Joakim Jonsson; Mikael Skorpil; Lennart Blomqvist; Sara Strandberg; Katrine Riklund; Lars Beckman; Camilla Thellenberg-Karlsson
Journal:  Phys Imaging Radiat Oncol       Date:  2021-02-24

5.  Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?

Authors:  Alison Tree; Caroline Jones; Aslam Sohaib; Vincent Khoo; Nicholas van As
Journal:  Radiat Oncol       Date:  2013-10-02       Impact factor: 3.481

6.  Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.

Authors:  Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu
Journal:  J Contemp Brachytherapy       Date:  2018-06-29

7.  The clinical guiding value of a radiomics model for androgen deprivation therapy for prostate cancer.

Authors:  Na Yu; Baoping Wang; Jialiang Ren; Hui Wu; Yang Gao; Aishi Liu; Guangming Niu
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.